Current situation and prospect of minimal residual disease in pediatric T cell acute lymphoblastic leukemia
10.3760/cma.j.cn121090-20240701-00239
- VernacularTitle:儿童急性T淋巴细胞白血病微小残留病研究现状及展望
- Author:
Fengfeng NIU
1
;
Chao GAO
1
Author Information
1. 国家儿童医学中心、首都医科大学附属北京儿童医院检验中心，儿童血液病与肿瘤分子分型北京市重点实验室，儿科重大疾病研究教育部重点实验室，北京 100045
- Publication Type:Journal Article
- From:
Chinese Journal of Hematology
2025;46(1):97-102
- CountryChina
- Language:Chinese
-
Abstract:
Pediatric T-cell acute lymphoblastic leukemia (T-ALL) has been attracted much attention due to its high aggressiveness and complexity of treatment. Recently, with the development of technology and clinical research, the curative effect of T-ALL in children has been significantly improved. However, the presence of minimal residual disease (MRD) is still a key factor affecting the outcomes of children with T-ALL. With the continuous development of detection methods, the clinical applications of real-time quantitative PCR, multi-parameter flow cytometry, and high-throughput sequencing technology, MRD can be detected accurately to achieve personalized and precise treatment for each patient. The purpose of this article is to review the current detection methods of MRD in T-ALL, the clinical significance of MRD monitoring and evaluation in multi-agent combined chemotherapy and hematopoietic stem cell transplantation, and applying MRD to measure the responsiveness and effectiveness of new therapies in recent T-ALLs. Research directions and potential treatment strategies in the near future were also proposed.
